Payment overview · 2025
General Payments
$907.58
51 reported records · 13 companies
Healthcare provider profile · identity verified
Cp Dunbar, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEESVILLE, SC · NPI 1205821865
Verified facts
What the public records show
CMS Open Payments records show Cp Dunbar, MD received $907.58 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $246.95 | 27.2% | 12 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $209.80 | 23.1% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.04 | 14.9% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.88 | 7.9% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $46.98 | 5.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.16 | 3.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.32 | 3.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.64 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.18 | 2.7% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.35 | 2.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.07 | 2.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.93 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $907.58 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $209.80 | 13 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $209.80 | 13 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $209.80 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.32 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.09 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.34 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.88 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.97 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 686 | 132 |
| Morphine Sulfate Er | Morphine Sulfate | 672 | 77 |
| Oxycodone Hcl | Oxycodone Hcl | 477 | 87 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 283 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 80 |
| Gabapentin | Gabapentin | 204 | 61 |
| Lisinopril | Lisinopril | 203 | 75 |
| Xtampza Er | Oxycodone Myristate | 192 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 57 |
| Oxycontin | Oxycodone Hcl | 163 | 26 |
| Clonazepam | Clonazepam | 158 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 49 |
| Methadone Hcl | Methadone Hcl | 146 | 20 |
| Metformin Hcl | Metformin Hcl | 144 | 49 |
| Furosemide | Furosemide | 142 | 40 |
| Pregabalin | Pregabalin | 131 | 21 |
| Ozempic | Semaglutide | 127 | 41 |
| Trazodone Hcl | Trazodone Hcl | 123 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 30 |
| Omeprazole | Omeprazole | 120 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 42 |
| Topiramate | Topiramate | 110 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 43 |
| Buspirone Hcl | Buspirone Hcl | 98 | 26 |
| Prednisone | Prednisone | 94 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 30 |
| Famotidine | Famotidine | 84 | 29 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 83 | 20 |
| Warfarin Sodium | Warfarin Sodium | 83 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 30 |
| Eliquis | Apixaban | 79 | 19 |
| Allopurinol | Allopurinol | 77 | 25 |
| Hydromorphone Hcl | Hydromorphone Hcl | 77 | 14 |
| Tramadol Hcl | Tramadol Hcl | 77 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 24 |
| Sertraline Hcl | Sertraline Hcl | 74 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Valsartan | Valsartan | 61 | 23 |
| Losartan Potassium | Losartan Potassium | 56 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 21 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Cephalexin | Cephalexin | 51 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 18 |
| Potassium Chloride | Potassium Chloride | 49 | 20 |
| Lorazepam | Lorazepam | 47 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | 17 |
| Meloxicam | Meloxicam | 42 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Azithromycin | Azithromycin | 33 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 32 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Linzess | Linaclotide | 23 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 23 | 23 |
| Hydromorphone Er | Hydromorphone Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | 11 |
| Alprazolam | Alprazolam | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Hydrocodone Bitartrate Er | Hydrocodone Bitartrate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $907.58 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, FARXIGA, FLOWTRIEVER CATHETER, S, NALOCET, NURTEC ODT, OTEZLA, Ozempic, PROLATE, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TANLOR, TRELEGY ELLIPTA, VRAYLAR, WAKIX, Wegovy, Xhance, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error